Built from public records only: federal awards, patents, filings and papers.Is this you? Contact Noair Lab to claim this profile, correct it or hide it.
2016First federal award
$18.2MFederal grants as PI31 awards
1Patents grantedLatest Jul 11, 2023
715Papers22,964 citations
Federal awards and patents by year
AwardsPatents
31 awards · $18.2M
| Date | Agency | Award | Amount | Company |
|---|---|---|---|---|
| Aug 27, 2026 | NIH | SBIR Phase I Long-term formulation for combination antiviral treatment of HIV | $307K | COLLABORATIONS PHARMACEUTICALS INC |
| May 28, 2025 | NIH | SBIR Phase II Machine learning approaches to predict Acetylcholinesterase inhibition and model applications | $1.3M | COLLABORATIONS PHARMACEUTICALS INC |
| Sep 4, 2024 | NIH | SBIR Phase II Machine learning approaches to predict Acetylcholinesterase inhibition and model applications | $727K | COLLABORATIONS PHARMACEUTICALS INC |
| Sep 15, 2023 | NIH | SBIR Phase I Preclinical development of a Nipah Virus inhibitor | $295K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 23, 2023 | NIH | STTR Phase II MegaTrans – human transporter machine learning models | $865K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 2, 2023 | NIH | SBIR Phase II MegaTox for analyzing and visualizing data across different screening systems | $855K | COLLABORATIONS PHARMACEUTICALS INC |
| May 23, 2023 | NIH | SBIR Phase II Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease | $1.5M | COLLABORATIONS PHARMACEUTICALS INC |
| Sep 2, 2022 | NIH | STTR Phase II MegaTrans – human transporter machine learning models | $865K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 1, 2022 | NIH | SBIR Phase II MegaTox for analyzing and visualizing data across different screening systems | $855K | COLLABORATIONS PHARMACEUTICALS INC |
| Jul 26, 2022 | NIH | SBIR Phase II Centralized assay datasets for modelling support of small drug discovery organizations | $855K | COLLABORATIONS PHARMACEUTICALS INC |
| Jun 15, 2022 | NIH | SBIR Phase II Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease | $3.0M | COLLABORATIONS PHARMACEUTICALS INC |
| Jun 9, 2022 | NIH | SBIR Phase II Manufacture of an intracerebroventricular Enzyme Replacement Therapy for CLN1 Batten Disease | $1.5M | COLLABORATIONS PHARMACEUTICALS INC |
| Apr 12, 2022 | NIH | SBIR Phase I New therapeutic approaches to identifying molecules for opioid abuse treatment | $256K | COLLABORATIONS PHARMACEUTICALS INC |
| Dec 9, 2021 | NIH | SBIR Phase I Machine learning approaches to predict Acetylcholinesterase inhibition | $256K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 24, 2021 | NIH | SBIR Phase II Centralized assay datasets for modelling support of small drug discovery organizations | $855K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 5, 2020 | NIH | SBIR Phase I MegaTox for analyzing and visualizing data across different screening systems | $125K | COLLABORATIONS PHARMACEUTICALS INC |
| Nov 15, 2019 | NIH | SBIR Phase I MegaPredict for predicting natural product uses and their drug interactions | $156K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 29, 2019 | NIH | SBIR Phase I MegaTox for analyzing and visualizing data across different screening systems | $225K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 15, 2019 | NIH | SBIR Phase I MegaPredict for predicting natural product uses and their drug interactions | $225K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 12, 2019 | NIH | SBIR Phase I MegaPredict for predicting natural product uses and their drug interactions | $69K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 9, 2019 | NIH | SBIR Phase II Centralized assay datasets for modelling support of small drug discovery organizations | $189K | COLLABORATIONS PHARMACEUTICALS INC |
| Jul 29, 2019 | NIH | SBIR Phase II Centralized assay datasets for modelling support of small drug discovery organizations | $693K | COLLABORATIONS PHARMACEUTICALS INC |
| Apr 25, 2019 | NIH | SBIR Phase I Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $55K | COLLABORATIONS PHARMACEUTICALS INC |
| Mar 21, 2019 | NIH | STTR Phase I MegaTrans – human transporter machine learning models | $211K | COLLABORATIONS PHARMACEUTICALS INC |
| Jan 29, 2019 | NIH | SBIR Phase I Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $127K | COLLABORATIONS PHARMACEUTICALS INC |
| Sep 15, 2018 | NIH | SBIR Phase I Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $412K | COLLABORATIONS PHARMACEUTICALS INC |
| Sep 5, 2018 | NIH | SBIR Phase I Enzyme Replacement Therapy For Infantile Onset Neuronal Ceroid Lipofuscinoses | $230K | COLLABORATIONS PHARMACEUTICALS INC |
| Jul 26, 2018 | NIH | SBIR Phase II Centralized assay datasets for modelling support of small drug discovery organizations | $694K | COLLABORATIONS PHARMACEUTICALS INC |
| Feb 7, 2018 | NIH | STTR Phase I Structure-guided optimization of an in vivo active small molecule antitubercular targeting KasA | $225K | COLLABORATIONS PHARMACEUTICALS INC |
| Dec 15, 2016 | NIH | SBIR Phase I Centralized assay datasets for modelling support of small drug discovery organizations | $150K | COLLABORATIONS PHARMACEUTICALS INC |
| Aug 5, 2016 | NIH | STTR Phase I Optimization of small molecule triazine antituberculars for in vivo efficacy | $149K | COLLABORATIONS PHARMACEUTICALS INC |
2 patents as inventor
- US 11696914COLLABORATIONS PHARMACEUTICALS INCJul 11, 2023
- US COLLABORATIONS PHARMACEUTICALS INC—
Matched by the first inventor’s name and the patent’s company.
Peer ranks
Federal funding#9
Awards as PI#4
Patents#155
Companies
- COLLABORATIONS PHARMACEUTICALS INCLinked by awards · Biotech
Federal awards through Oct 21, 2026 and patents through Oct 20, 2026. Awards come from NIH, NSF and other agency records that name a principal investigator; DoD and NASA contract awards do not, so they are not shown here. Researchers are matched by name and company.